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Introduction: Patients with trauma-induced coagulopathies may benefit from the use of antifibrinolytic agents, such as tranexamic acid 
(TXA). This study evaluated the safety and efficacy of TXA in civilian adults hospitalized with traumatic hemorrhagic shock.
Methods: Patients who sustained blunt or penetrating trauma with signs of hemorrhagic shock from June 2014 through July 2018 
were considered for TXA treatment. A retrospective control group was formed from patients seen in the same past five years who were 
not administered TXA and matched based on age, gender, Injury Severity Score (ISS), and mechanism of injury (blunt vs penetrating 
trauma). The primary outcome of this study was mortality measured at 24 hours, 48 hours, and 28 days. Secondary outcomes included 
total blood products transfused, hospital length of stay (LOS), intensive care unit LOS, and adverse events. We conducted three pre-
specified subgroup analyses to assess outcomes of patients, including (1) those who were severely injured (ISS >15), (2) those who 
sustained significant blood loss (≥10 units of total blood products transfused), and (3) those who sustained blunt vs penetrating trauma.
Results: Propensity matching yielded two cohorts: the hospital TXA group (n = 280) and a control group (n = 280). The hospital TXA 
group had statistically lower mortality at 28 days (1.1% vs 5%, odds ratio [OR] [0.21], (95% confidence interval [CI], 0.06, 0.72)) and 
used fewer units of blood products (median = 4 units, interquartile range (IQR) = [1, 10] vs median=7 units, IQR = [2, 12.5] for the 
hospital TXA and control groups, respectively, (95% CI for the difference in median, -3 to -1). There were no statistically significant 
differences between groups with regard to 24-hour mortality (1.1% vs 1.1%, OR = 1, 95% CI, 0.20, 5.00), 48-hour mortality (1.1% vs 
1.4%, OR [0.74], 95% CI, 0.17, 3.37), hospital LOS (median= 9 days, IQR = (5, 16) vs median =12 days IQR = (6, 22.5) for the hospital 
TXA and control groups, respectively, 95% CI for the difference in median = (-5 to 0)), and incidence of thromboembolic events (eg, deep 
vein thrombosis, pulmonary embolism) during hospital stay (0.7% vs 0.7% for the hospital TXA and control group, respectively, OR [1], 
95% CI, 0.14 to 7.15). We conducted subgroup analyses on patients with ISS>15, patients transfused with ≥10 units of blood products, 
and blunt vs penetrating trauma. The results indicated lower 28-day mortality for ISS>15 (1.8% vs 7.1%, OR [0.23], 95% CI, 0.06 to 
0.81) and blunt trauma  (0.6% vs 6.3%, OR [0.09], 95% CI, 0.01 to 0.75); fewer units of blood products for penetrating trauma (median 
= 2 units, IQR = (1, 8) vs median = 8 units, IQR = (5, 15) for the hospital TXA and control groups, respectively, 95% CI for the difference 
in median = (-6 to -3)), and ISS>15 (median = 7 units, IQR = (2, 14) vs median = 8.5 units, IQR = (4, 16) for the hospital TXA and control 
groups, respectively, 95% CI for the difference in median, -3 to 0). 
Conclusion: The current study demonstrates a statistically significant reduction in mortality after TXA administration at 28 days, but not 
at 24 and 48 hours, in patients with traumatic hemorrhagic shock. [West J Emerg Med. 2020;21(2)217-225.]
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Population Health Research Capsule
What do we already know about this issue?
Prior studies assessing tranexamic acid (TXA) 
use in civilian and military trauma resuscitation 
demonstrate a promising effect on mortality 
reduction and a limited side-effect profile. 
What was the research question?
We aimed to assess the safety and efficacy 
of TXA in civilian adults hospitalized with 
traumatic hemorrhagic shock. 
What was the major finding of the study?
The current study demonstrates a statistically 
significant reduction in mortality after TXA 
administration at 28 days, but not at 24 and 48 
hours, in patients with traumatic hemorrhagic 
shock. 
How does this improve population health?
Traumatic injury is a major cause of death in 
both developed and developing nations. TXA use 
represents a feasible measure toward reducing 
loss of life due to traumatic exsanguinating injury. 
INTRODUCTION
Trauma is the leading cause of death in individuals between 
the ages of one and 44 years in the United States and accounts 
for more than 5.8 million deaths worldwide.1 It is estimated 
that by 2020 more than one in 10 people will die from trauma-
related injuries.1 A subset of traumatic injury deaths are a result 
of hemorrhagic shock that is refractory to optimal resuscitation 
efforts.2 Trauma-induced coagulopathy is present in up to 35% of 
patients with severe injury on arrival to the emergency department 
(ED).3 Patients with an uncorrected coagulopathy such as 
hyperfibrinolysis are at the greatest risk of death.4 
Trauma-induced depletion of coagulation factors 
and dysregulation of the coagulation system may lead to 
hemodynamic instability, resulting in cardiovascular collapse. 
Trauma-induced coagulopathies have been associated with a 
significant increase in the risk of trauma-induced mortality.3,5-8 
Although scant evidence indicates that tranexamic acid (TXA) 
may increase mortality in cases of fibrinolysis shutdown, patients 
with trauma-induced coagulopathies may benefit from the use 
of antifibrinolytic agents. TXA, for example, is a synthetic 
derivative of the amino acid lysine that exerts its antifibrinolytic 
effect through the reversible blockade of lysine-binding sites on 
plasminogen molecules.9
TXA administration has been studied in both the prehospital 
and hospital settings. Wafausade et al reported a decreased 
mortality after TXA administration in a prehospital setting in 
Germany.10 Similar conclusions were reported about the benefit of 
TXA administration in a prehospital setting.11 The 2010 Clinical 
Randomization of an Antifibrinolytic in Significant Hemorrhage 
2 (CRASH-2) study was the first to report the use of TXA in the 
management of civilian traumatic hemorrhage in a hospital setting. 
CRASH-2 described a 1.5% reduction in all-cause mortality at 28 
days for patients who received TXA for trauma-related injuries.12 
Subgroup analyses of CRASH-2 in subsequent years 
demonstrated that the administration of TXA within three hours 
of injury resulted in a 2.4% decrease in death due to bleeding.13 
The efficacy of TXA to reduce mortality was further supported 
by the Military Application of Tranexamic Acid in Trauma 
Emergency Resuscitation (MATTERS) study, a retrospective, 
observational study that analyzed TXA administration at a military 
hospital in Afghanistan.14 Additionally, Cole et al suggested TXA 
administration provided survival benefit for severely injured 
patients.15 However, Boutonnet et al studied TXA in a civilian 
hospital setting and reported no reduction in hospital mortality 
associated with TXA alone.16
There has been some discrepancy in current literature 
regarding the potential side effects of TXA, such as venous 
thromboembolic events (VTE), including deep vein thrombosis 
(DVT) and pulmonary embolism (PE). While some studies have 
not identified an increase in incidence of VTE associated with 
TXA, others have found TXA to be an independent risk factor 
for increased incidence of VTE.11,12,14,17-19 Thus, there is a need 
to continue to further evaluate the safety of TXA use within the 
hospital trauma setting.
To date, there is limited evidence on the optimal timing 
and use of TXA in cases of traumatic hemorrhagic shock in the 
civilian hospital setting.12,14-16 Our goal was to evaluate the safety 
and efficacy of early TXA use in a civilian hospital setting for 
cases of traumatic hemorrhagic shock within a developed North 
American trauma system. We hypothesized that administration 
of TXA upon arrival to the trauma center would be associated 
with reduced mortality in cases of traumatic hemorrhagic shock. 
The primary outcome of this study was mortality measured at 24 
hours, 48 hours, and 28 days. Secondary outcomes included the 
following: total blood products transfused during resuscitation 
efforts and during the hospital stay; the hospital and intensive care 
unit (ICU) lengths of stay (LOS); and the incidence of known 
adverse events associated with TXA administration including 
thromboembolic events (eg, DVT, PE), myocardial infarction, 
and neurological events (eg, stroke, seizure). 
METHODS
This civilian hospital-based study is a prospective, 
observational cohort study with a retrospective comparison. The 
current study was initiated in June 2014 at two trauma centers in 
Southern California: Arrowhead Regional Medical Center (Level 
2 trauma center), and Loma Linda University Medical Center 
(Level 1 trauma center). Data collection at both trauma centers 
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concluded in July 2018. The hospital TXA study, including 
administration protocols, was approved by the institutional review 
boards of each receiving trauma center. At each institution, TXA 
was approved for use in traumatic hemorrhagic shock injury 
within the emergency department (ED) as well as incorporated 
into the massive transfusion protocol and administered uniformly 
between centers based on the study protocol.
Data Collection, Protocols, Outcomes
All patients ≥18-years-old who sustained blunt or penetrating 
trauma with signs and symptoms of hemorrhagic shock were 
considered for TXA treatment upon meeting inclusion criteria 
(Table 1). The original design of Cal-PAT (California Prehospital 
Antifibrinolytic Therapy) included a prehospital arm and a 
hospital arm.11 The investigators followed the same protocol 
to ensure consistency of inclusion/exclusion criteria. Patient 
selection in the hospital setting was determined by inclusion 
criteria upon patient arrival to the trauma center. Trauma and ED 
team members underwent a standardized training session on the 
inclusion and exclusion criteria for the study, guidelines for TXA 
candidate identification, protocols for TXA administration, and 
the medication’s side-effect profile. The choice of 120 beats per 
minute for heart rate (HR) for the prehospital arm was added by 
an agreement with the State of California EMS Agency Authority 
at the time of the approval of the original protocol.
TXA was delivered in two doses as per the protocol used 
in the CRASH-2 trial.20 The first dose was one gram of TXA in 
100 milliliters (mL) of 0.9% normal saline infused as a bolus 
over 10 minutes via intravenous (IV) or intraosseous access. 
This first dose was administered by registered nurses as soon as 
feasible after the patient’s initial assessment and screening by 
the trauma team. Identification of study patients receiving TXA 
was achieved through a wristband labeled “TXA” and/or verbal 
communication at patient hand-off by team members. Following 
the completion of the first dose infusion, a second dose of TXA 
infusion at one gram in 100 mL of 0.9% normal saline, was 
administered via IV over eight hours.
A control group was formed from patients evaluated at each 
respective trauma center within five years prior to the conclusion 
of data collection for this report. The control group patients 
met the same study criteria (Figure 1) and were matched to the 
“Hospital TXA” group patients through the use of propensity 
scoring based upon age, gender, injury severity score (ISS), 
and mechanism of injury. The biostatistician in charge of the 
matching process was blinded to patient outcomes to avoid bias 
in the matching process. There were no institutional changes in 
transfusion and ICU policy within the past five years in either 
trauma center that would have affected our outcomes. In addition, 
the same protocol were followed regardless of the change in 
trauma team members. 
We abstracted data for selected subjects from the electronic 
health record (EHR) for each patient within each hospital. 
Follow-up to determine mortality outcomes after hospital 
discharge were abstracted from the EHR and trauma registry. In 
select cases, we conducted direct chart review and, in cases of 
missing data, study investigators contacted the patient(s) and/or 
the families directly to confirm survival outcomes. All patients 
included in this study were accounted for via hospital follow-up 
or direct communication. 
Statistical Analysis
We conducted all statistical analyses using SAS software 
for Windows, version 9.3 (SAS Institute, Cary, North Carolina). 
Descriptive statistics were presented as means and standard 
deviation or median and interquartile range (IQR) for continuous 
variables, along with frequencies and proportions for categorical 
variables. We used propensity score matching based on age, 
gender, ISS, and mechanism of injury to form the hospital TXA 
and control groups. Matching of each patient for the hospital 
TXA and control groups were performed within the trauma 
registry of each respective center involved. We conducted chi-
square analyses to identify whether there were differences in 
mortality at 24 hours, 48 hours, and 28 days between the hospital 
TXA and control groups. 
Inclusion criteria Exclusion criteria
The hospital use of TXA should be considered for all trauma patients 
that meet any of the following criteria:
• Blunt or penetrating trauma with signs and symptoms of hemor-
rhagic shock within three hours of injury.
o Systolic blood pressure of less than 90 mmHg upon arrival to   
designated trauma centers.
o Heart rate >120.
o Estimated blood loss of 500 milliliters 
o Bleeding not controlled by direct pressure or tourniquet.
• Major amputation of any extremity above the wrists and above the 
ankles.
• Any patient <18 years of age.
• Any patient more than three hours post-injury.
• Any patient with an active thromboembolic event (within the last 
24 hours) – ie, active stroke, myocardial infarction or pulmonary 
embolism. 
• Any patient with a hypersensitivity or anaphylactic reaction to TXA.
• Any patient that received prehospital TXA.
• Traumatic arrest with more than five minutes of cardiopulmonary 
resuscitation without return of vital signs.
• Penetrating cranial injury.
• Traumatic brain injury with brain matter exposed.
• Isolated drowning or hanging victims.
• Documented cervical cord injury with motor deficits.
TXA, tranexamic acid, mmHG, millimeters of mercury.
Table 1. Patients Inclusion and exclusion criteria provided to clinicians at receiving trauma centers.
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Independent t-tests were conducted to identify whether there 
were differences of continuous variables (eg, age) between the 
hospital TXA and control groups. We conducted Wilcoxon rank 
sum tests to identify whether the median of some continuous 
variables (eg, hospital LOS) was different between the hospital 
TXA and control groups. Based on the original study design, 
three pre-specified subgroup analyses were conducted to assess 
outcomes of patients, including (1) those who were severely 
injured (ISS >15), (2) those who sustained significant blood loss 
(≥10 units of total blood products transfused), and (3) those who 
sustained blunt vs penetrating trauma. All statistical analyses 
were two-sided. P-value<0.05 was considered to be statistically 
significant. 
RESULTS
A total of 280 patients were included in the hospital TXA 
group. A propensity matching process selected 280 patients from 
a control group (n = 1049). Thus, a total of 560 patients were 
included in the final analysis. Table 2 presents the overall analysis 
results. The hospital TXA group had statistically lower mortality 
at the 28-day mark (1.1% vs 5%, odds ratio [OR] [0.21], 95% 
confidence interval (CI), 0.06 to 0.72) and used fewer units of 
blood products (median =4 units, IQR = [1, 10] vs median = 7 
units, IQR = [2, 12.5] for the hospital TXA and control groups, 
respectively, 95% CI for the difference in median = (-3 to -1)). 
There were no statistically significant differences between groups 
in regard to 24-hour mortality (1.1% vs 1.1%, OR = 1, 95% CI, 
0.20, 5.00; 48-hour mortality (1.1% vs 1.4%, OR [0.74], 95% 
CI, 0.17, 3.37); hospital LOS (median = 9 days, IQR = (5, 16) 
vs median = 12 days, IQR = (6, 22.5) for the hospital TXA and 
control groups, respectively, 95% CI for the difference in median 
= (-5 to 0)), and the incidence of thromboembolic events (eg, 
DVT, PE) during hospital stay (0.7% vs 0.7% for the hospital 
TXA and control groups, respectively, OR [1], 95% CI, 0.14 to 
7.15). The average time of TXA administration from injury was 
100 minutes for ground transportation and 166 minutes for air 
transportation.
A first subgroup analysis was conducted among patients 
with ISS>15 (Table 3). The hospital TXA group had statistically 
lower mortality at 28 days (1.8% vs 7.1%, OR [0.23], 95% CI, 
0.06 to 0.81). Moreover, the hospital TXA group used fewer units 
of blood products (median = 7 units, IQR = (2, 14) vs median = 
8.5 units, IQR = (4, 16) for the hospital TXA and control groups, 
respectively, 95% CI for the difference in median = (-3 to 0)). We 
found no statistically significant differences in the 24-hour and 
48-hour mortality, as well as in other secondary outcomes (Table 
3). 
We conducted a second subgroup analysis among patients 
who were transfused ≥10 units of total blood product (Table 4). 
There were no statistically significant differences in 24-hour, 48-
Hospital TXA Group Gontrol Group
Figure 1. Patient flow chart for the hospital tranexamic acid (TXA) and control groups. 
ISS, Injury Severity Score; LLUMC, Loma Linda University Medical Center; ARMC, Arrowhead Regional Medical Center.
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hour, and 28-day mortality, and all secondary outcomes (Table 
4). A final subgroup analysis was conducted based on blunt vs 
penetrating trauma (Table 5). Among patients who sustained 
blunt trauma, the hospital TXA group had statistically lower 
mortality at 28 days (0.6% vs 6.3%, OR [0.09], 95% CI, 0.01 to 
0.75). There was no statistically significant difference in the 24-
hour and 48-hour mortality, and secondary outcomes (Table 5). 
Among patients who sustained penetrating trauma, the 
hospital TXA group used fewer units of blood products (median 
= 2 units, IQR = (1, 8) vs median = 8 units, IQR = (5, 15) for the 
hospital TXA and control groups, respectively, 95% CI for the 
difference in median = (-6 to -3)), and had a shorter hospital LOS 
(median = 6 days, IQR = (2.5, 14.5) vs median = 11 days, IQR = 
(7, 21.5) for the hospital TXA and control groups, respectively, 
95% CI for the difference in median = (-7 to -1)). There was no 
statistically significant difference in the 24-hour, 48-hour, and 28-
day mortality, and other secondary outcomes (Table 5). 
DISCUSSION
This study completed in July 2018, marks one of the first 
large-scale prospective studies assessing the effects of TXA 
administration when used for traumatic hemorrhagic shock in 
a civilian hospital setting within a developed North American 
trauma system. Hospital TXA administration was associated with 
a statistically lower 28-day mortality. Secondary outcomes in 
this study also demonstrated a statistically significant decrease in 
hospital LOS. 
The current study suggests that TXA may be more effective 
in patients who are more severely injured and require more 
units of blood products. The benefit of TXA particularly among 
the most severely injured trauma patients was consistent with 
multiple other studies including CRASH-2 and MATTERS.12,14 
Despite the fact that the TXA groups were more severely injured, 
both studies identified a decrease in mortality.12,14 Additionally, 
patients requiring a massive blood transfusion benefited more 
from the TXA administration.14 Both benefits were identified 
despite the inability to quantify the degree of fibrinolysis prior to 
TXA treatment.
TXA has been hypothesized to exert its beneficial effect on 
trauma patients via its antifibrinolytic properties. Specifically, 
Hospital TXA group 
(n = 280)
Control group 
(n = 280) Statistic with 95% CI
Outcomes
Mortality at 24 hours 3 (1.1%) 3 (1.1%) 1 (0.20, 5.00)†
Mortality at 48 hours 3 (1.1%) 4 (1.4%) 0.74 (0.17, 3.37)†
Mortality at 28 days 3 (1.1%) 14 (5%) 0.21 (0.06, 0.72)†
Total blood product, units, median (Q1, Q3) 4 (1, 10) 7 (2, 12.5) -2 (-3, -1)‡
Hospital LOS, days, median (Q1, Q3) 9 (5, 16) 12 (6, 22.5) -2 (-5, 0)‡
ICU LOS, days, median (Q1, Q3) 4 (3, 8) 4 (2, 10) 0 (-1, 1)‡
Adverse event during hospital stay 1 (0.14, 7.15)†
VTE 2 (0.7%) 2 (0.7%)
None 278 (99.3%) 278 (99.3%)
Factors
Blunt trauma percentage 159 (56.8%) 160 (57.1%) 0.99 (0.71, 1.38)†
Male percentage 236 (84.3%) 241 (86.1%) 0.87 (0.54, 1.38)†
Age, years, mean ± SD 38.89 ± 15.98 37.91 ± 18.15 0.98 (-1.86, 3.82)*
SBP, mmHg, mean ± SD 99.32 ± 17.84 102.32 ± 23.27 -3.00 (-6.51, 0.50)*
Discharge ISS, median (Q1, Q3) 17 (10, 26) 17 (12, 26) 0 (0, 2)‡
GCS, median (Q1, Q3) 15 (11, 15) 15 (14, 15) 0 (0,0)‡
Table 2. Comparison of outcomes and factors between hospital tranexamic acid (TXA) and control groups.
†Values were presented as the odds ratio (use the control group as the reference) and the corresponding 95% confidence interval. Chi-square 
tests were conducted to assess the statistical significance. If the 95% confidence interval contains 1, then there was not statistically significant 
difference between the two groups.
‡ Values were presented as the median and IQR for the difference between the two groups (defined as the hospital TXA group less the control 
group). Wilcoxon rank sum tests were conducted to assess the statistical significance. If the 95% confidence interval contains 0, then there 
was not statistically significant difference between the two groups.
*Values were presented as the means and 95% corresponding confidence interval for the difference between the two groups (defined as the 
hospital TXA group less the control group). An independent t-tests were conducted to assess the statistical significance. If the 95% confidence 
interval contains 0, then there was not statistically significant difference between the two groups.
TXA, tranexamic acid; CI; confidence interval; LOS, length of stay; ICU, intensive care unit; ISS, Injury Severity Score; Q1, 25th percentile; 
Q3, 75th percentile; SBP, systolic blood pressure; SD, standard deviation; GCS, Glasgow Coma Scale; VTE, venous thromboembolic events.
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Blood product ≥ 10 Units (n=176)
Hospital TXA group 
(n=76)
Control group 
(n=100) Statistic with 95% CI
Outcomes
Mortality at 24 hours 3 (4%) 3 (3%) 1.33 (0.26, 6.77)†
Mortality at 48 hours 3 (4%) 4 (4%) 0.99 (0.21, 4.54)†
Mortality at 28 days 3 (4%) 11 (11%) 0.34 (0.09, 1.24)†
Total Blood Product, units, median (Q1, Q3) 15.5 (12, 23.5) 16 (12, 25) -1 (-3, 1)‡
Hospital LOS, days, median (Q1, Q3) 16 (8, 23) 16 (7, 28.5) -1 (-8, 6)‡
ICU LOS, days, median (Q1, Q3) 6 (3, 13) 6 (4, 13) 0 (-2, 2)‡
Factors
Blunt trauma percentage 50 (65.8%) 54 (54%) 1.64 (0.88, 3.03)†
Male percentage 58 (76.3%) 88 (88%) 0.44 (0.20, 0.98)†
Age, years, mean ± SD 41.04 ± 15.78 35.41 ± 16.61 5.63 (0.75, 10.51)*
SBP, mmHg, mean ± SD 98.24 ± 16.94 107.21 ± 23.39 -8.98 (-15.35, -2.60)*
Discharge ISS, median (Q1, Q3) 22 (17, 29) 22 (16, 29) 0 (-2, 4)‡
GCS, median (Q1, Q3) 14 (7, 15) 14 (13, 15) 0 (-1, 0)‡
Table 4. Subgroup analysis: comparison of outcomes and factors between hospital tranexamic acid (TXA) and control groups among 
patients who were transfused ≥10 units of blood product.
Table 3. Subgroup analysis: comparison of outcomes and factors between hospital tranexamic acid (TXA) and control groups among 
patients with Injury Severity Score >15.
ISS>15 (n = 337)
Hospital TXA group 
(n=167)
Control group 
(n=170) Statistic with 95% CI
Outcomes
Mortality at 24 hours 3 (1.8%) 3 (1.8%) 1.01(0.20, 5.12)†
Mortality at 48 hours 3 (1.8%) 4 (2.4%) 0.76 (0.17, 3.44)†
Mortality at 28 days 3 (1.8%) 12 (7.1%) 0.23 (0.06, 0.81)†
Total Blood Product, units, median (Q1, Q3) 7 (2, 14) 8.5 (4, 16) -2 (-3, 0)‡
Hospital LOS, days, median (Q1, Q3) 13 (7, 17) 14 (7, 27) -2 (-6, 2)‡
ICU LOS, days, median (Q1, Q3) 5 (3, 10) 5 (3, 13) 0 (-1, 1)‡
Factors
Blunt trauma percentage 116 (69.5%) 98 (57.7%) 1.67 (1.07, 2.62)†
Male percentage 132 (79%) 146 (85.9%) 0.62 (0.35, 1.10)†
Age, years, mean ± SD 39.23 ± 16.44 35.79 ± 16.84 3.43 (-0.13, 7.00)*
SBP, mmHg, mean ± SD 98.66 ± 17.8 101.26 ± 23.77 -2.60 (-7.18, 1.99)*
Discharge ISS, median (Q1, Q3) 24 (17, 29) 24 (17, 29) 0 (-1, 1) ‡
GCS, median (Q1, Q3) 14 (8, 15) 15 (14, 15) 0 (0, 0) ‡
†Values were presented as the odds ratio (use the control group as the reference) and the corresponding 95% confidence interval. Chi-square 
tests were conducted to assess the statistical significance. If the 95% confidence interval contains 1, then there was not statistically significant 
difference between the two groups.
‡ Values were presented as the median and IQR for the difference between the two groups (defined as the hospital TXA group less the control 
group). Wilcoxon rank sum tests were conducted to assess the statistical significance. If the 95% confidence interval contains 0, then there 
was not statistically significant difference between the two groups.
*Values were presented as the means and 95% corresponding confidence interval for the difference between the two groups (defined as the 
hospital TXA group less the control group). An independent t-tests were conducted to assess the statistical significance. If the 95% confidence 
interval contains 0, then there was not statistically significant difference between the two groups.
TXA, tranexamic acid; CI; confidence interval; LOS, length of stay; ICU, intensive care unit; Q1, 25th percentile; Q3, 75th percentile; SBP, 
systolic blood pressure; mmHg, millimeters of mercury; SD, standard deviation; GCS, Glasgow Coma Scale; ISS, Injury Severity Score.
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TXA has been thought to reduce mortality by preventing 
exsanguination on the day of injury.21 After significant trauma, 
coagulopathies may begin almost immediately and can rapidly 
progress to life-threatening scenarios.6-8 These coagulopathies 
have been postulated to be driven in part by excessive activation 
of the thrombomodulin-protein C pathway.22 Following tissue 
hypoperfusion in the setting of traumatic injury, protein C is 
activated.3 This subsequent rise in activated protein C leads to 
proteolytic cleavage and inactivation of procoagulant factors V 
and VIII. 
In addition, activated protein C neutralizes plasminogen 
activator inhibitor-1 causing increased concentrations of tissue 
plasminogen activator and further progression of fibrinolysis.23 
These mechanisms combine and can lead to acute traumatic 
coagulopathies.22 Research has demonstrated that high levels of 
activated protein C on admission in trauma patients have been 
associated with increased mortality, longer hospital stay, and 
increased transfusion requirements.22 Although not specifically 
measured in our study, the role of activated protein C in 
coagulopathies may show why TXA’s ability to inhibit the excess 
plasminogen is crucial in preventing mortality.
We observed a statistically significant decrease in 28-day 
mortality, suggesting that TXA may exert an effect beyond 
the limitation of blood loss and treatment of hyperfibrinolysis. 
This may be due to the long-term effects of limiting profound 
hypoperfusion in the setting of trauma and the long-term benefits 
in controlling bleeding with TXA therapy. The conversion of 
plasminogen to plasmin in the clotting pathway exacerbates 
and leads to overactivation of the inflammatory response.24 
Plasmin has been shown to have a direct effect on macrophages, 
Blunt trauma (n = 319) Penetrating trauma (n=241)
Hospital TXA 
group 
(n = 159)
Control group 
(n = 160)
Statistic with 
95% CI**
Hospital TXA 
group 
(n = 121)
Control group 
(n = 120)
Statistic with 
95% CI
Outcomes
Mortality at 24 hours 1 (0.6%) 1 (0.6%) 1.00 (0.06, 16.2)† 2 (1.7%) 2 (1.7%) 0.99 (0.14, 7.16)†
Mortality at 48 hours 1 (0.6%) 2 (1.3%) 0.5 (0.04, 5.57)† 2 (1.7%) 2 (1.7%) 0.99 (0.14, 7.16)†
Mortality at 28 days 1 (0.6%) 10 (6.3%) 0.09 (0.01, 0.75)† 2 (1.7%) 4 (3.3%) 0.49 (0.09, 2.71)†
Total Blood Product, 
units, median (Q1, Q3)
5 (2, 11) 5 (2, 11) 0 (-1, 1)‡ 2 (1, 8) 8 (5, 15) -5 (-6, -3)‡
Hospital LOS, days, 
median (Q1, Q3)
13 (7, 16) 14 (5, 23) 0 (-6, 4)‡ 6 (2.5, 14.5) 11 (7, 21.5) -4 (-7, -1)‡
ICU LOS, days, 
median (Q1, Q3)
5 (3, 10) 5 (2, 10) 1 (0, 2)‡ 3 (1, 5) 4 (2, 9) -1 (-2, 0)‡
Factors
Male percentage 122 (76.7%) 126 (78.8%) 0.89 (0.52, 1.51)† 114 (94.2%) 115 (95.8%) 0.71 (0.22, 2.30)†
Age, years, 
mean ± SD
42.55 ± 17.34 44.34 ± 19.09 -1.80 (-5.81, 2.22)* 34.08 ± 12.53 29.33 ± 12.46 4.76 (1.59, 7.93)*
SBP, mmHg, 
mean ± SD
99.25 ± 17.06 100.23 ± 21.4 -0.98 (-5.28, 3.33)* 99.4 ± 18.9 105.46 ± 25.61 -6.06 (-11.94, -0.17)*
Discharge ISS, 
median (Q1, Q3)
22 (14, 27) 17 (12, 26) 1 (0, 4)‡ 14 (9, 19) 17 (11, 25) 3 (1,5)‡
GCS, median 
(Q1, Q3)
15 (10, 15) 14.5 (13.5, 15) 0 (0, 0)‡ 15 (13, 15) 15 (14, 15) 0 (0,0)‡
Table 5. Subgroup analysis: comparison of outcomes and factors between hospital tranexamic acid (TXA) and control groups for blunt 
vs penetrating trauma.
†Values were presented as the odds ratio (use the control group as the reference) and the corresponding 95% confidence interval. Chi-square 
tests were conducted to assess the statistical significance. If the 95% confidence interval contains 1, then there was not statistically significant 
difference between the two groups.
‡Values were presented as the median and IQR for the difference between the two groups (defined as the hospital TXA group less the control 
group). Wilcoxon rank sum tests were conducted to assess the statistical significance. If the 95% confidence interval contains 0, then there 
was not statistically significant difference between the two groups.
*Values were presented as the means and 95% corresponding confidence interval for the difference between the two groups (defined as the 
hospital TXA group less the control group). An independent t-tests were conducted to assess the statistical significance. If the 95% confidence 
interval contains 0, then there was not statistically significant difference between the two groups.
TXA, tranexamic acid; CI; confidence interval; LOS, length of stay; ICU, intensive care unit; Q1, 25th percentile; Q3, 75th percentile; SBP, 
systolic blood pressure; mmHg, millimeters of mercury; SD, standard deviation; GCS, Glasgow Coma Scale; ISS, Injury Severity Score.
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leading to the transcription of the proinflammatory cytokines 
tumor necrosis factor-alpha and interleukin-6.25 Excess 
plasmin can cause detachment of endothelial cells leading to 
apoptosis and release of radical oxygen species.24 Aside from 
the proinflammatory effects, plasmin has also been known to 
cause platelet hypofunction.24 TXA’s inhibitory effect on the 
conversion of plasminogen to plasmin may contribute to its anti-
inflammatory properties leading to the extended benefits observed 
in our study. The exact mechanism is likely multi-factorial and 
needs to be more clearly elucidated. 
The efficacy of TXA when used during fibrinolysis and 
hyperfibrinolysis is controversial. Recent studies demonstrate 
that TXA may be associated with an increased risk of fibrinolytic 
shutdown when monitored via thromboelastography (TEG).26 In 
another study within a civilian hospital setting, patients receiving 
TXA required more total blood products and had a statistically 
significant increase in mortality.27 However, this study has 
limitations, given that it is a retrospective study and includes 
older patients with higher injury severity and hypotension 
compared to patients in other studies.12,27 
The incidence of VTE associated with TXA administration 
in a trauma setting has also been controversial. Johnston et al 
conducted a retrospective, follow-up study to MATTERs to re-
examine TXA use within the military hospital setting.17 They 
reported a higher incidence of VTE in patients receiving TXA 
and found that use of TXA was an independent risk factor for 
VTE with an overall rate of 15.6% VTE.17 The prevention of clot 
dissolution via TXA inhibition of plasmin may heighten risks of 
VTE by promoting thrombus.18 A civilian study performed by 
Myers et al reported a 7.4% and 15.5% incidence rate of VTE 
for the control and TXA groups, respectively.19 However, the 
reported incidence rate of VTE by Myers and Johnston was much 
higher than other reported VTE incidence rates ranging from 
0.36% to 1.8%.11,20,28 
The current study suggests an incidence rate of 0.7% for 
VTE among patients who received TXA, which is within range 
of previously reported incidence rates.11,20,28 The two studies that 
reported TXA administration as an independent risk factor for 
VTE had several significant limitations including the following: 
retrospective data collection; possible patient selection bias;  
small sample size; population differences between control groups 
and TXA groups; VTE surveillance bias; and variation in trauma 
settings.17,18 Future prospective research is warranted to examine 
the incidence of VTE among adult trauma patients.
LIMITATIONS
First, this study was limited by design. The prospective, non-
randomized cohort design did not allow TXA to be administered 
in a blinded fashion. Providers and physicians were aware of 
TXA administration, which may have affected the level of care 
provided and assessments of outcome. However, given that the 
primary outcome was mortality, this impact was likely minimal. 
Second, we acknowledge an inability to account for certain 
potential confounding factors. This includes the variability of 
total transport time to the ED, which contributed to variability of 
initial TXA administration time. Additionally, despite following 
the same study protocol, patients were included from two trauma 
centers in the same geographic area that may follow slightly 
different institutional policy and procedure. To reduce the impact 
of these differences on patient outcomes, control patients were 
matched by trauma center. These factors in addition to minimal 
inherent differences between the TXA and control groups may 
limit the generalizability of these results.
Lastly, we did not integrate the use of TEG into this 
study; thus, we were unable to assess the combined role of 
TEG and TXA regarding patient outcomes. Debate continues 
regarding whether TEG can accurately predict the need and 
use of TXA.21,29 TEG is not routinely available in many trauma 
centers; however, those centers have continued including TXA 
administration in their current trauma resuscitation standards. 
Further investigation into the combined use of both TXA 
administration and TEG is warranted.14
CONCLUSION
The current study demonstrates a statistically significant 
reduction in mortality after TXA administration at 28 days, but 
not at 24  and 48 hours, in patients with traumatic hemorrhagic 
shock. Future prospective research is warranted to further 
evaluate the benefits and side effects of TXA use among adult 
civilian trauma patients on a larger scale.
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